MarketPeel
Insider Trading Intelligence
KG

Keith A. Goldan

SNDX
CHIEF FINANCIAL OFFICER · SYNDAX PHARMACEUTICALS INC · CIK 0001495411
FILING MIX · LIFETIME73%/27%
BUYS
19
SELLS
7
TOTAL VALUE
$12.62M
COMPANIES
2
ACTIVE SINCE
Jun 2022
HOLDINGS NOW
172,003
AVG SELL PX
$17.90
TRADE KIND
SHOWING 26 / 26
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 10 pending
Forward-return performance of every backtestable P/S trade by Keith A. Goldan, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+71.43%+0.45%+0.05%+0.40%-1.24%
14d7+71.43%+1.91%-0.14%+2.05%+1.50%
30d7+57.14%+14.72%-0.18%+14.90%+15.45%
60d7+42.86%+8.75%-0.58%+9.33%-1.38%
90d7+57.14%+10.68%+4.26%+6.42%-8.17%
180d7(2 pending)+60.00%+27.27%+9.84%+17.44%-23.18%
1y7(3 pending)+50.00%+23.44%+19.18%+4.26%-4.39%
2y7(5 pending)+50.00%-31.48%+39.35%-70.84%-70.84%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
SNDX · 139,252 shares · as of Jun 1, 2026
057,500115,000172,500230,0002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 19 buys / 7 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Financial Officer
1,177$18.99$22.4K139,252Jun 1, 2026Jun 2, 2026View →
ABEO
ABEONA THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
32,75132,751Apr 1, 2026Apr 7, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Financial Officer
3,410$21.03$71.7K140,429Feb 9, 2026Feb 10, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Financial Officer
2,082$20.62$42.9K143,839Feb 6, 2026Feb 6, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
118,000$20.43$2.41M118,000Feb 4, 2026Feb 6, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
30,750145,921Feb 4, 2026Feb 6, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
21,500115,171Feb 4, 2026Feb 6, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Financial Officer
1,219$8.48$10.3K93,671Jan 30, 2026Feb 6, 2026View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALEGRANT
Gift
1,22492,452Dec 1, 2025Dec 1, 2025View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Financial Officer
1,226$8.43$10.3K93,676Jul 31, 2025Aug 7, 2025View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Financial Officer
1,296$9.29$12.0K92,450Jul 16, 2025Jul 18, 2025View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Financial Officer
3,00093,746May 19, 2025May 19, 2025View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Financial Officer
3,777$15.50$58.6K90,746Feb 10, 2025Feb 12, 2025View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
23,40094,523Feb 5, 2025Feb 7, 2025View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
110,500$14.65$1.62M110,500Feb 5, 2025Feb 7, 2025View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
18,50071,123Feb 5, 2025Feb 7, 2025View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Financial Officer
1,250$20.03$25.0K52,623Jun 14, 2024Jun 17, 2024View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
35,00039,673Feb 7, 2024Feb 9, 2024View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
11,70051,373Feb 7, 2024Feb 9, 2024View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
70,000$22.28$1.56M70,000Feb 7, 2024Feb 9, 2024View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Financial Officer
1,183$17.42$20.6K4,673Jan 31, 2024Feb 9, 2024View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASE
Chief Financial Officer
862$18.12$15.6K3,490Jul 31, 2023Feb 9, 2024View →
SNDX
SYNDAX PHARMACEUTICALS INC
SALE
Chief Financial Officer
577$22.31$12.9K2,628Jun 13, 2023Jun 14, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
110,000$28.55$3.14M110,000Feb 2, 2023Feb 3, 2023View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
3,2053,205Jun 13, 2022Jun 15, 2022View →
SNDX
SYNDAX PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
230,000$15.60$3.59M230,000Jun 13, 2022Jun 15, 2022View →
Other insiders · SNDX
Loading peer insiders…
About this filer
CIK 0001495411
ROLE
Chief Financial Officer
PRIMARY
SNDX
COMPANIES
2
ACTIVE SINCE
Jun 2022
MARKETPEEL · /INSIDER/0001495411DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback